<DOC>
	<DOCNO>NCT01660243</DOCNO>
	<brief_summary>This study conduct investigate efficacy MT-9938 compare placebo 2 week , continue evaluate efficacy additional 6 week , explore effect reduction itch intensity health-related Quality Life ( QoL ) domains , especially recent research suggest positive correlation overall survival patient group . The study consist follow phase : Screening ( 1 2 week ) , Run ( 1 week ) , double-blind Treatment ( 8 week ) , Washout ( 1 week ) culminate Follow-up Visit ( 1 week last dose ) .</brief_summary>
	<brief_title>Efficacy Safety MT-9938 Treatment Uremic Pruritus Subjects With End-stage Renal Disease Receiving Hemodialysis</brief_title>
	<detailed_description>This study terminate insufficient patient recruitment . There safety concern .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<criteria>On stable hemodialysis least 3 month Has stable function arteriovenous fistula , graft venous access Has continue ( uncontrolled ) uremic pruritus despite standard care institution Has severe pruritus , determine qualify score ≥3 Itch Severity Score Scale ( 0 4 ) either day night week prior Screening Visit Has know drug addiction prescription , nonprescription , herbal natural drug , successfully pass drug screen test Women men whose partner childbearing potential agree practice medically acceptable method birth control agree continue regimen throughout duration study Capable understand respond subject questionnaire , understands purpose risk study , give write informed consent Has rat his/her NRS score day least 5 day 7 day Runin Phase Has severe pruritus , determine qualify mean bad NRS score day ≥5 ( 11 point NRS ) end 1week Runin Phase Current , clinically significant medical comorbidities Abnormal liver dysfunction Pruritus attribute mainly disease unrelated kidney disease Calcium x phosphorus product &gt; 80 mg2/dL2 hemoglobin &lt; 7 g/dL parathyroid hormone level &gt; 1000 pg/mL Screening Received ultraviolet B treatment within 30 day prior Screening Started change psychotropic medication within 14 day prior Screening Is receive opioid antagonist opioid agonist within 7 day prior Screening willing abstain medication study . Started change medication , cream emollient include overthecounter oil bath treatment relief pruritus within 7 day prior Screening Has know hypersensitivity opioids study drug ingredient Is currently participate investigational drug device clinical study participate study within 30 day prior start Screening Female subject know pregnant nursing Is consider suitable inclusion study opinion Investigator Has current suicidal ideation intent act specific plan intent suicidal behavior time subject 's life</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pruritus</keyword>
	<keyword>Renal dialysis</keyword>
	<keyword>Receptors , Opioid , kappa</keyword>
	<keyword>Sleep Disorders</keyword>
	<keyword>Quality Life</keyword>
</DOC>